HomeAI · summaries
Storia in 5 fonti
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug targets multidrug-resistant Gram-negative pathogens and showed strong efficacy in Phase 3 trials. The approval highlights growing urgency around antimicrobial resistance and limited treatment options.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic
Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drugs potential to treat…
- ·
Wockhardt secures US FDA approval for antibiotic Zaynich
Wockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. This breakthrough drug targets superbugs…
- ·
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…
- ·
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…
- ·
thehindubusinessline.com
Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich
Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and zidebactam, a non-β-lactam antibacterial and β-lactamase…
- ·
morningstar.com
Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult…
Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract…
- ·
If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala
Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual…
- ·
timesofindia.indiatimes.com
'USFDA nod for Zaynich a major boost'
NEW DELIH: The US Food and Drug Administration's approval of Wockhardt's Zaynich, a first-in-class 'breakthrough antibiotic' for severe drug-resistant infections, opens up a…
- ·
healio.com
FDA approves Zaynich for complicated UTIs
The FDA approved Zaynich as an intravenous treatment for complicated urinary tract infections, including pyelonephritis, in adults, according to a press release from the…
- ·
Zaynich's blockbuster potential lifts Wockhardt's long-term outlook
Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting…
- ·
Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract…
- ·
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?
Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company…